December 10, 2018
Jennifer Barrett, Associate Editor
Overall response rate and survival in patients with relapsed AML treated with azacitidine plus nivolumab and ipilimumab may be superior to azacitidine plus nivolumab.


Jennifer Barrett, Associate Editor
Officials with the FDA have granted accelerated approval to venetoclax (Venclexta) for treating newly-diagnosed acute myeloid leukemia (AML) in patients who are ineligible for intensive induction chemotherapy.
Jennifer Barrett, Associate Editor
Adcetris being evaluated for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressiong peripheral T-cell lymphomas in combination with cyclophosphamide, doxorubicin, and prednisone.
SPT Staff
Pembrolizumab (Keytruda) is indicated for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.
Kristen Coppock, MA, Editor
Udenyca (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. 
Jennifer Barrett, Associate Editor
Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults with plaque psoriasis who are candidates for systemic therapy or phototherapy. 
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us